Turkmenistan is the first to register the second Russian EpiVacCorona vaccine
The second Russian-made vaccine, EpiVacCorona, developed by the State Research Center for Virology and Biotechnology Vector, has passed the registration procedure in Turkmenistan. The corresponding certificate was issued by the Center on Registration of Medicines and State Control under the Ministry of Health and Medical Industry of Turkmenistan. Earlier, expert analysis of the pharmacological and pharmacopoeial committees of the Center has been carried out. As ORIENT was informed by the government source of Turkmenistan, after the issuance of the registration certificate for the vaccine, the purchase and use of this drug in our country for the prevention of viral infection is allowed. EpiVacCorona was registered in Russia in October 2020 and passed post-registration clinical trials. Turkmenistan became the first state to officially approve the use of vaccine on its territory, following the manufacturing country – Russian Federation – where this vaccine was officially registered. Earlier, on January 18, 2021, the Ministry of Health and Medical Industry of Turkmenistan made state registration of the Sputnik V vaccine developed by the Gamaleya Research Center. It is a vector vaccine, that is, produced based on adenovirus, which used as a delivery mechanism of the outer coat genetic material of coronavirus to human body. The new vaccine was created based on one of the promising synthetic platforms, and it is a peptide vaccine; it consists of artificially synthesized short fragments of viral proteins – peptides, through which the immune system learns and subsequently recognizes and neutralizes the virus. According to experts, the vaccine is characterized by a sufficiently high level of safety. To date, representatives of the Central Research Institute of Epidemiology of Rospotrebnadzor are on a visit to Ashgabat. A large-scale production of the EpiVacCorona vaccine will begin in February, according to Russian Prime Minister Mikhail Mishustin,
ORIENT news
